[{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Antaros Medical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical","highestDevelopmentStatusID":"11","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Voglibose","moa":"Alpha glucosidase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"National Center for Global Health and Medicine, Japan","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"AMP-activated protein kinase (AMPK)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"National Center for Global Health and Medicine, Japan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for Global Health and Medicine, Japan \/ Sumitomo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"National Center for Global Health and Medicine, Japan \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Joslin Diabetes Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Joslin Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joslin Diabetes Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Joslin Diabetes Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Miami","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Johns Hopkins University \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ Endo Pharm"},{"orgOrder":0,"company":"Men's Health Boston","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Men's Health Boston","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Men's Health Boston \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Men's Health Boston \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Upsher-Smith Laboratories | Endo Pharm | Acerus Pharmaceuticals | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Upsher-Smith Laboratories | Endo Pharm | Acerus Pharmaceuticals | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Upsher-Smith Laboratories | Endo Pharm | Acerus Pharmaceuticals | AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"University of Miami","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Miami \/ Clarus Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Bassett Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Glucomannan","moa":"anti-inflammatory agents (acetic acid derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bassett Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bassett Healthcare \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bassett Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"LMC Diabetes & Endocrinology","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LMC Diabetes & Endocrinology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"LMC Diabetes & Endocrinology \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"LMC Diabetes & Endocrinology \/ Bausch Health"},{"orgOrder":0,"company":"Duta Wacana Christian University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DLBS5055","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Duta Wacana Christian University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duta Wacana Christian University \/ Dexa Medica","highestDevelopmentStatusID":"11","companyTruncated":"Duta Wacana Christian University \/ Dexa Medica"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cinacalcet Hydrochloride","moa":"Calcium sensing receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kyowa Kirin","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Kyowa Kirin"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cinacalcet Hydrochloride","moa":"Calcium sensing receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cinacalcet Hydrochloride","moa":"Calcium sensing receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"Carnitine O-palmitoyltransferase 1, muscle isoform; Xanthine dehydrogenase\/oxidase; Liver carboxylesterase 1; Myeloperoxidase; Carnitine O-palmitoyltransferase 1, liver isoform; Solute carrier family 22 member 4; Organic cation\/carnitine transporter 2; Carnitine O-acetyltransferase; Mitochondrial basic amino acids transporter; Mitochondrial carnitine\/acylcarnitine carrier protein; Peroxisomal carnitine O-octanoyltransferase; Carnitine O-palmitoyltransferase 2, mitochondrial","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea University Anam Hospital \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"VeroScience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bromocriptine Mesylate","moa":"D2-like dopamine receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ VeroScience","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ VeroScience"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veterans Medical Research Foundation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Veterans Medical Research Foundation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kyunghee University Medical Center","sponsor":"Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kyunghee University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyunghee University Medical Center \/ Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Kyunghee University Medical Center \/ Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Kun-Ho Yoon","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kun-Ho Yoon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kun-Ho Yoon \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Kun-Ho Yoon \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kun-Ho Yoon","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alogliptin Benzoate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kun-Ho Yoon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kun-Ho Yoon \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Kun-Ho Yoon \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Anagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Anagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Anagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed"},{"orgOrder":0,"company":"George Washington University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Washington University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"George Washington University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"Marcus Borchert","sponsor":"ikfe-CRO | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Marcus Borchert","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marcus Borchert \/ ikfe-CRO | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Marcus Borchert \/ ikfe-CRO | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","sponsor":"Pi Research and Development Center | Acme Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BANGLADESH","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders \/ Pi Research and Development Center | Acme Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders \/ Pi Research and Development Center | Acme Laboratories"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omarigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix VA Health Care System","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Phoenix VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phoenix VA Health Care System \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Phoenix VA Health Care System \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"George Washington University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Washington University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"George Washington University \/ AstraZeneca"},{"orgOrder":0,"company":"Cook County Health","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cook County Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook County Health \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Cook County Health \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Prof. Dr. Thomas Forst","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Prof. Dr. Thomas Forst","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof. Dr. Thomas Forst \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prof. Dr. Thomas Forst \/ Undisclosed"},{"orgOrder":0,"company":"Dokkyo Medical University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dokkyo Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dokkyo Medical University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Dokkyo Medical University \/ Merck & Co"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Merck & Co"},{"orgOrder":0,"company":"Lund University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Lund University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lund University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Lund University \/ Merck & Co"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GWT-TUD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GWT-TUD \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Georgetown University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Merck & Co"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Merck & Co"},{"orgOrder":0,"company":"LMC Diabetes & Endocrinology","sponsor":"Merck & Co | Syreon Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LMC Diabetes & Endocrinology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LMC Diabetes & Endocrinology \/ Merck & Co | Syreon Corporation","highestDevelopmentStatusID":"11","companyTruncated":"LMC Diabetes & Endocrinology \/ Merck & Co | Syreon Corporation"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Medical College of Wisconsin \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Medical College of Wisconsin \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Merck & Co"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Merck & Co | Temple University | University of Michigan | Ohio University","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Merck & Co | Temple University | University of Michigan | Ohio University","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Merck & Co | Temple University | University of Michigan | Ohio University"},{"orgOrder":0,"company":"Woman's","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Woman's","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woman's \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Woman's \/ Merck & Co"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trelagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trelagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trelagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trelagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Trelagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Samsung Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Hospital, Strasbourg","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Hospital, Strasbourg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Strasbourg \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Strasbourg \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Centro de Diabetes Curitiba","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centro de Diabetes Curitiba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Diabetes Curitiba \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Centro de Diabetes Curitiba \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Jos\u00e9 Fernando Vilela-Martin MD PhD","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dr. Jos\u00e9 Fernando Vilela-Martin MD PhD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Jos\u00e9 Fernando Vilela-Martin MD PhD \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Dr. Jos\u00e9 Fernando Vilela-Martin MD PhD \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Carbohydrate","year":"2018","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Ohio State University","sponsor":"The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ohio State University \/ The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Ohio State University \/ The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbott Laboratories \/ Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix VA Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Phoenix VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phoenix VA Health Care System \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Phoenix VA Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Oxford \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Oxford \/ Novo Nordisk"},{"orgOrder":0,"company":"Sansum Diabetes Research Institute","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sansum Diabetes Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sansum Diabetes Research Institute \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Sansum Diabetes Research Institute \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Colorado, Denver \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Novo Nordisk"},{"orgOrder":0,"company":"Geisinger Clinic","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Geisinger Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geisinger Clinic \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Geisinger Clinic \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Washington","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Novo Nordisk"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ Novo Nordisk"},{"orgOrder":0,"company":"GSK","sponsor":"Duke Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Duke Clinical Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Duke Clinical Research Institute"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ PPD"},{"orgOrder":0,"company":"GSK","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ PPD"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Massachusetts General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Central Hospital, Nancy, France \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Central Hospital, Nancy, France \/ Eli Lilly"},{"orgOrder":0,"company":"University of Palermo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Palermo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Palermo \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Palermo \/ AstraZeneca"},{"orgOrder":0,"company":"GSK","sponsor":"Wake Forest Baptist Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Wake Forest Baptist Health","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Wake Forest Baptist Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"Carl T. Hayden VA Medical Center","sponsor":"American Diabetes Association | Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Carl T. Hayden VA Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carl T. Hayden VA Medical Center \/ American Diabetes Association | Amylin Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Carl T. Hayden VA Medical Center \/ American Diabetes Association | Amylin Pharmaceuticals"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"University at Buffalo \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ AstraZeneca"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"University at Buffalo \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Aarhus University Hospital | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Aarhus University Hospital | Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Aarhus \/ Aarhus University Hospital | Novo Nordisk"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Novo Nordisk | University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Novo Nordisk | University of Copenhagen","highestDevelopmentStatusID":"11","companyTruncated":"University of Aarhus \/ Novo Nordisk | University of Copenhagen"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Slagelse Hospital | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Slagelse Hospital | Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Rigshospitalet \/ Slagelse Hospital | Novo Nordisk"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Leiden University Medical Center \/ Novo Nordisk"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Leiden University Medical Center \/ Novo Nordisk"},{"orgOrder":0,"company":"ikfe-CRO","sponsor":"Novo Nordisk | IKFE Institute for Clinical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"ikfe-CRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ikfe-CRO \/ Novo Nordisk | IKFE Institute for Clinical Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"ikfe-CRO \/ Novo Nordisk | IKFE Institute for Clinical Research and Development"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix VA Health Care System","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Phoenix VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phoenix VA Health Care System \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Phoenix VA Health Care System \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Miami","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Novo Nordisk"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mount Sinai Hospital, Canada \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Mount Sinai Hospital, Canada \/ Novo Nordisk"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mount Sinai Hospital, Canada \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Mount Sinai Hospital, Canada \/ Novo Nordisk"},{"orgOrder":0,"company":"CHU de Quebec-Universite Laval","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"CHU de Quebec-Universite Laval","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHU de Quebec-Universite Laval \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"CHU de Quebec-Universite Laval \/ Novo Nordisk"},{"orgOrder":0,"company":"Vancouver General Hospital","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Vancouver General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vancouver General Hospital \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Vancouver General Hospital \/ Novo Nordisk"},{"orgOrder":0,"company":"Tulane University School of Medicine","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tulane University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulane University School of Medicine \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University School of Medicine \/ Novo Nordisk"},{"orgOrder":0,"company":"Peter Rossing","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Peter Rossing","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peter Rossing \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Peter Rossing \/ Novo Nordisk"},{"orgOrder":0,"company":"Bo Feldt-Rasmussen","sponsor":"Novo Nordisk | The GCP unit at Copenhagen University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bo Feldt-Rasmussen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bo Feldt-Rasmussen \/ Novo Nordisk | The GCP unit at Copenhagen University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Bo Feldt-Rasmussen \/ Novo Nordisk | The GCP unit at Copenhagen University Hospital"},{"orgOrder":0,"company":"Ildiko Lingvay","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ildiko Lingvay","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ildiko Lingvay \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Ildiko Lingvay \/ Novo Nordisk"},{"orgOrder":0,"company":"Tina Vilsboll","sponsor":"Novo Nordisk | Rigshospitalet | Hvidovre University Hospital | Herlev Hospital | Hillerod Hospital, Denmark | University of Copenhagen | Novo Nordisk Foundation Center for Basic Metabolic Research | Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tina Vilsboll","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tina Vilsboll \/ Novo Nordisk | Rigshospitalet | Hvidovre University Hospital | Herlev Hospital | Hillerod Hospital, Denmark | University of Copenhagen | Novo Nordisk Foundation Center for Basic Metabolic Research | Aarhus University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Tina Vilsboll \/ Novo Nordisk | Rigshospitalet | Hvidovre University Hospital | Herlev Hospital | Hillerod Hospital, Denmark | University of Copenhagen | Novo Nordisk Foundation Center for Basic Metabolic Research | Aarhus University Hospital"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Novo Nordisk"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Lixisenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Matthew J. Budoff","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Matthew J. Budoff","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Matthew J. Budoff \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Matthew J. Budoff \/ Eli Lilly"},{"orgOrder":0,"company":"Inje University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Inje University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Inje University \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Inje University \/ Allergan"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Max-Planck-Institute Psychiatry","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Max-Planck-Institute Psychiatry","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Max-Planck-Institute Psychiatry \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Max-Planck-Institute Psychiatry \/ Novo Nordisk"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Rabin Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Children's Hospital of Fudan University | Suzhou Municipal Hospital | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Maternal and Child Health Hospital of Hubei | Nantong Univ","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Suzhou Municipal Hospital | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Maternal and Child Health Hospital of Hubei | Nantong Univ","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Suzhou Municipal Hospital | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Henan University of Science and Technology | Maternal and Child Health Hospital of Hubei | Nantong Univ"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"The Children's Hospital of Zhejiang University School of Medicine | The Second Hospital of Anhui Medical University | Guangzhou Women and Children's Medical Center | First People's Hospital of Hangzhou | Qilu Hospital of Shandong University | Zhejiang Pro","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ The Children's Hospital of Zhejiang University School of Medicine | The Second Hospital of Anhui Medical University | Guangzhou Women and Children's Medical Center | First People's Hospital of Hangzhou | Qilu Hospital of Shandong University | Zhejiang Pro","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ The Children's Hospital of Zhejiang University School of Medicine | The Second Hospital of Anhui Medical University | Guangzhou Women and Children's Medical Center | First People's Hospital of Hangzhou | Qilu Hospital of Shandong University | Zhejiang Pro"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"The First Affiliated Hospital of Henan University of Traditional Chinese Medicine | First Affiliated Hospital of Harbin Medical University | The Second Hospital of Hebei Medical University | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Union ","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ The First Affiliated Hospital of Henan University of Traditional Chinese Medicine | First Affiliated Hospital of Harbin Medical University | The Second Hospital of Hebei Medical University | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Union ","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ The First Affiliated Hospital of Henan University of Traditional Chinese Medicine | First Affiliated Hospital of Harbin Medical University | The Second Hospital of Hebei Medical University | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Union "},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Tongji Hospital | First Affiliated Hospital, Sun Yat-Sen University | Capital Medical University | Children's Hospital of Fudan University | The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | First Affiliated Hospital, Sun Yat-Sen University | Capital Medical University | Children's Hospital of Fudan University | The First Hospital of Jilin University","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | First Affiliated Hospital, Sun Yat-Sen University | Capital Medical University | Children's Hospital of Fudan University | The First Hospital of Jilin University"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"GeneScience Pharmaceuticals Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Polyethylene Glycol Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ GeneScience Pharmaceuticals Co Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Tongji Hospital \/ GeneScience Pharmaceuticals Co Ltd"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Covance","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Covance"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Tigermed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Tigermed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0.64000000000000001,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Pfizer Inc"},{"orgOrder":0,"company":"Hotel Dieu de France Hospital","sponsor":"Nouvelle Soci\u00e9t\u00e9 Fran\u00e7aise d'Ath\u00e9roscl\u00e9rose | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"LEBANON","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hotel Dieu de France Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hotel Dieu de France Hospital \/ Nouvelle Soci\u00e9t\u00e9 Fran\u00e7aise d'Ath\u00e9roscl\u00e9rose | Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Hotel Dieu de France Hospital \/ Nouvelle Soci\u00e9t\u00e9 Fran\u00e7aise d'Ath\u00e9roscl\u00e9rose | Pfizer Inc"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pravastatin","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Samsung Medical Center \/ Daiichi Sankyo","highestDevelopmentStatusID":"11","companyTruncated":"Samsung Medical Center \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Nang Kuang Pharmaceutical Co. Ltd.","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pravastatin","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Nang Kuang Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nang Kuang Pharmaceutical Co. Ltd. \/ National Taiwan University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Nang Kuang Pharmaceutical Co. Ltd. \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rosuvamibe","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Linical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Linical","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Linical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Merck & Co"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Statin","moa":"HMG-CoA reductase (HMGCR)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Psyllium","moa":"Homeostasis","graph1":"Endocrinology","graph2":"Phase IV","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Hyaluronidase","moa":"Hyaluronic acid","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"RUSSIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Subetta","moa":"Immune","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"RUSSIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Subetta","moa":"Immune","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"||INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"INSR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Research Centre, Malaysia","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"MALAYSIA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Clinical Research Centre, Malaysia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Research Centre, Malaysia \/ Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"Clinical Research Centre, Malaysia \/ Medtronic plc"},{"orgOrder":0,"company":"Sciema UG","sponsor":"Innovative Diabetes Treatment Studies","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sciema UG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sciema UG \/ Innovative Diabetes Treatment Studies","highestDevelopmentStatusID":"11","companyTruncated":"Sciema UG \/ Innovative Diabetes Treatment Studies"},{"orgOrder":0,"company":"Hospital Universitario Central de Asturias","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hospital Universitario Central de Asturias","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitario Central de Asturias \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Universitario Central de Asturias \/ Sanofi"},{"orgOrder":0,"company":"IKFE Institute for Clinical Research and Development","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"IKFE Institute for Clinical Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IKFE Institute for Clinical Research and Development \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"IKFE Institute for Clinical Research and Development \/ Sanofi"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"BodyMedia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ BodyMedia","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ BodyMedia"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Cairo University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"EGYPT","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cairo University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cairo University \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Cairo University \/ Sanofi"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Atlanta Diabetes Associates | University of Southern California | Rainier Clinical Research Center | Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Atlanta Diabetes Associates | University of Southern California | Rainier Clinical Research Center | Mannkind","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Atlanta Diabetes Associates | University of Southern California | Rainier Clinical Research Center | Mannkind"},{"orgOrder":0,"company":"LMC Diabetes & Endocrinology","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LMC Diabetes & Endocrinology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LMC Diabetes & Endocrinology \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"LMC Diabetes & Endocrinology \/ Sanofi"},{"orgOrder":0,"company":"Informed Data Systems, Inc.","sponsor":"Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Informed Data Systems, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Informed Data Systems, Inc. \/ Mannkind","highestDevelopmentStatusID":"11","companyTruncated":"Informed Data Systems, Inc. \/ Mannkind"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Insulet Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Insulet Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Insulet Corporation"},{"orgOrder":0,"company":"Diabetes and Glandular Disease Clinic","sponsor":"Mannkind | DexCom","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Diabetes and Glandular Disease Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diabetes and Glandular Disease Clinic \/ Mannkind | DexCom","highestDevelopmentStatusID":"11","companyTruncated":"Diabetes and Glandular Disease Clinic \/ Mannkind | DexCom"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Basal Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin Analog","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"Stanford University \/ Medtronic plc"},{"orgOrder":0,"company":"Mountain Diabetes and Endocrine Center","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mountain Diabetes and Endocrine Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mountain Diabetes and Endocrine Center \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Mountain Diabetes and Endocrine Center \/ Novo Nordisk"},{"orgOrder":0,"company":"Kathleen Dungan","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kathleen Dungan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kathleen Dungan \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Kathleen Dungan \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Sansum Diabetes Research Institute","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sansum Diabetes Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sansum Diabetes Research Institute \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Sansum Diabetes Research Institute \/ Novo Nordisk"},{"orgOrder":0,"company":"LMC Diabetes & Endocrinology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LMC Diabetes & Endocrinology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LMC Diabetes & Endocrinology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LMC Diabetes & Endocrinology \/ Undisclosed"},{"orgOrder":0,"company":"Merete Bechmann Christensen","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Degludec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merete Bechmann Christensen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merete Bechmann Christensen \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Merete Bechmann Christensen \/ Novo Nordisk"},{"orgOrder":0,"company":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te","sponsor":"Novo Nordisk | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te \/ Novo Nordisk | Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te \/ Novo Nordisk | Abbott Laboratories"},{"orgOrder":0,"company":"Buckinghamshire Healthcare NHS Trust","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Buckinghamshire Healthcare NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buckinghamshire Healthcare NHS Trust \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Buckinghamshire Healthcare NHS Trust \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Joslin Diabetes Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Joslin Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joslin Diabetes Center \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Joslin Diabetes Center \/ Sanofi"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi"},{"orgOrder":0,"company":"Third Affiliated Hospital, Sun Yat-sen University","sponsor":"Guangdong Department of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Third Affiliated Hospital, Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Third Affiliated Hospital, Sun Yat-sen University \/ Guangdong Department of Science and Technology","highestDevelopmentStatusID":"11","companyTruncated":"Third Affiliated Hospital, Sun Yat-sen University \/ Guangdong Department of Science and Technology"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"ikfe-CRO","sponsor":"IKFE Institute for Clinical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"ikfe-CRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ikfe-CRO \/ IKFE Institute for Clinical Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"ikfe-CRO \/ IKFE Institute for Clinical Research and Development"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Weill Cornell Medical College in Qatar","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"QATAR","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Weill Cornell Medical College in Qatar","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medical College in Qatar \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Weill Cornell Medical College in Qatar \/ Novo Nordisk"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Population Health Research Institute \/ Hamilton Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Population Health Research Institute \/ Hamilton Health Sciences"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Population Health Research Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Population Health Research Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Population Health Research Institute \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Population Health Research Institute \/ Merck & Co"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Population Health Research Institute \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Population Health Research Institute \/ Sanofi"},{"orgOrder":0,"company":"LMC Diabetes & Endocrinology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LMC Diabetes & Endocrinology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LMC Diabetes & Endocrinology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LMC Diabetes & Endocrinology \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Eli Lilly | Sanofi | AstraZeneca | Bristol Myers Squibb | DexCom | Bayer AG | Becton Dickinson | Medicomp | University of Texas System | US Department of Veterans Affairs | Biomedical Research Institute of New Mexico","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Eli Lilly | Sanofi | AstraZeneca | Bristol Myers Squibb | DexCom | Bayer AG | Becton Dickinson | Medicomp | University of Texas System | US Department of Veterans Affairs | Biomedical Research Institute of New Mexico","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Eli Lilly | Sanofi | AstraZeneca | Bristol Myers Squibb | DexCom | Bayer AG | Becton Dickinson | Medicomp | University of Texas System | US Department of Veterans Affairs | Biomedical Research Institute of New Mexico"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Life for a Child Program, Diabetes Australia","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | BADAS-Centre for Health Research and Implementation | Diabetic Association of Bangladesh","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Life for a Child Program, Diabetes Australia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life for a Child Program, Diabetes Australia \/ Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | BADAS-Centre for Health Research and Implementation | Diabetic Association of Bangladesh","highestDevelopmentStatusID":"11","companyTruncated":"Life for a Child Program, Diabetes Australia \/ Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | BADAS-Centre for Health Research and Implementation | Diabetic Association of Bangladesh"},{"orgOrder":0,"company":"Mira Zuidgeest","sponsor":"IMI Trials@Home consortium | Innovative Medicines Initiative | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mira Zuidgeest","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mira Zuidgeest \/ IMI Trials@Home consortium | Innovative Medicines Initiative | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Mira Zuidgeest \/ IMI Trials@Home consortium | Innovative Medicines Initiative | Sanofi"},{"orgOrder":0,"company":"Elaine Chow","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Elaine Chow","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elaine Chow \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Elaine Chow \/ Sanofi"},{"orgOrder":0,"company":"Kinderkrankenhaus auf der Bult","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kinderkrankenhaus auf der Bult","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinderkrankenhaus auf der Bult \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Kinderkrankenhaus auf der Bult \/ Sanofi"},{"orgOrder":0,"company":"ikfe-CRO","sponsor":"IKFE Institute for Clinical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"ikfe-CRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ikfe-CRO \/ IKFE Institute for Clinical Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"ikfe-CRO \/ IKFE Institute for Clinical Research and Development"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Insulin Glulisine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Sansum Diabetes Research Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sansum Diabetes Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sansum Diabetes Research Institute \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Sansum Diabetes Research Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Cipla","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Cipla"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin Lispro Mixture","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin Lispro Premix","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"HealthPartners Institute","sponsor":"International Diabetes Center at Park Nicollet | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Neutral Protamine Hagedorn Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HealthPartners Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HealthPartners Institute \/ International Diabetes Center at Park Nicollet | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"HealthPartners Institute \/ International Diabetes Center at Park Nicollet | Sanofi"},{"orgOrder":0,"company":"Hennepin Healthcare Research Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Neutral Protamine Hagedorn Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hennepin Healthcare Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hennepin Healthcare Research Institute \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Hennepin Healthcare Research Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Caninsulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Providence Health & Services \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Poxel","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma \/ Poxel"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iobitridol","moa":"iodine-containing contrast media","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Bayer AG | GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Iohexol","moa":"iodine-containing contrast media","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare \/ Bayer AG | GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GE Healthcare \/ Bayer AG | GUERBET"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Acarbose","moa":"Maltase-glucoamylase | Pancreatic alpha-amylase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Bayer AG"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"The Swedish Research Council | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Carbohydrate","year":"2010","type":"Inapplicable","leadProduct":"Acarbose","moa":"Maltase-glucoamylase | Pancreatic alpha-amylase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ The Swedish Research Council | Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Karolinska Institutet \/ The Swedish Research Council | Bayer AG"},{"orgOrder":0,"company":"Indiana University School of Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Acarbose","moa":"Maltase-glucoamylase | Pancreatic alpha-amylase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Indiana University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University School of Medicine \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Indiana University School of Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Fairhaven Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"QATAR","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methionine synthase reductase; Methylmalonic aciduria type A protein, mitochondrial; Cyanocobalamin reductase \/ alkylcobalamin dealkylase; Methylenetetrahydrofolate reductase (NADPH)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Fairhaven Health","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Fairhaven Health"},{"orgOrder":0,"company":"University Hospitals Cleveland Medical Center","sponsor":"Relypsa","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Spironolactone","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Hospitals Cleveland Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Cleveland Medical Center \/ Relypsa","highestDevelopmentStatusID":"11","companyTruncated":"University Hospitals Cleveland Medical Center \/ Relypsa"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)||Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Turku University Hospital","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Turku University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turku University Hospital \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Turku University Hospital \/ GSK"},{"orgOrder":0,"company":"ikfe-CRO","sponsor":"AstraZeneca | IKFE Institute for Clinical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"ikfe-CRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ikfe-CRO \/ AstraZeneca | IKFE Institute for Clinical Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"ikfe-CRO \/ AstraZeneca | IKFE Institute for Clinical Research and Development"},{"orgOrder":0,"company":"ikfe-CRO","sponsor":"Novartis Pharmaceuticals Corporation | IKFE Institute for Clinical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"ikfe-CRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ikfe-CRO \/ Novartis Pharmaceuticals Corporation | IKFE Institute for Clinical Research and Development","highestDevelopmentStatusID":"11","companyTruncated":"ikfe-CRO \/ Novartis Pharmaceuticals Corporation | IKFE Institute for Clinical Research and Development"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"American Diabetes Association | Amylin Pharmaceuticals | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | Amylin Pharmaceuticals | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | Amylin Pharmaceuticals | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"NHS Tayside","sponsor":"University of Southern Denmark | University of Dundee | Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Endocrinology","graph2":"Phase IV","graph3":"NHS Tayside","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NHS Tayside \/ University of Southern Denmark | University of Dundee | Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"11","companyTruncated":"NHS Tayside \/ University of Southern Denmark | University of Dundee | Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Bukwang Pharmaceutical Co., Ltd | ChunLab, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Tritriacontanoic Acid","moa":"Muscarinic acetylcholine receptor M5 (CHRM5)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Samsung Medical Center \/ Bukwang Pharmaceutical Co., Ltd | ChunLab, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Samsung Medical Center \/ Bukwang Pharmaceutical Co., Ltd | ChunLab, Inc."},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Manitoba Institute of Child Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Manitoba \/ Manitoba Institute of Child Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Manitoba Institute of Child Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Alabama at Birmingham \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Stryker"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"East Tennessee State University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"East Tennessee State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"East Tennessee State University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"East Tennessee State University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pioglitazone Hydrochloride","moa":"Peroxisome proliferator-activated receptor gamma||PPST agonists (thiazolidene derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Renexin","moa":"Platelet aggregation","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"Pusan National University Hospital","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lobeglitazone sulfate","moa":"PPAR?","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Pusan National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pusan National University Hospital \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Pusan National University Hospital \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPST agonists (thiazolidene derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPST agonists (thiazolidene derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPST agonists (thiazolidene derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPST agonists (thiazolidene derivatives)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"prostaglandins","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yonsei University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Yonsei University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yonsei University \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Yonsei University \/ Astellas Pharma"},{"orgOrder":0,"company":"Laboratoires Teriak","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TUNISIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Laboratoires Teriak","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratoires Teriak \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires Teriak \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Samjin pharm Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Samjin Pharmaceutical"},{"orgOrder":0,"company":"Fundacion Investigacion Interhospitalaria Cardiovascular","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Fundacion Investigacion Interhospitalaria Cardiovascular","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Investigacion Interhospitalaria Cardiovascular \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Fundacion Investigacion Interhospitalaria Cardiovascular \/ AstraZeneca"},{"orgOrder":0,"company":"Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla","sponsor":"Andaluz Health Service","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla \/ Andaluz Health Service","highestDevelopmentStatusID":"11","companyTruncated":"Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla \/ Andaluz Health Service"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Tel Aviv Medical Center | Sheba Medical Center | Meir Medical Center | Rambam Health Care Campus","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Tel Aviv Medical Center | Sheba Medical Center | Meir Medical Center | Rambam Health Care Campus","highestDevelopmentStatusID":"11","companyTruncated":"Rabin Medical Center \/ Tel Aviv Medical Center | Sheba Medical Center | Meir Medical Center | Rambam Health Care Campus"},{"orgOrder":0,"company":"University of Florida","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ AstraZeneca"},{"orgOrder":0,"company":"University of Florida","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ AstraZeneca"},{"orgOrder":0,"company":"CirQuest Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"CirQuest Labs","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CirQuest Labs \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CirQuest Labs \/ Undisclosed"},{"orgOrder":0,"company":"Juan J. Badimon","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Juan J. Badimon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juan J. Badimon \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Juan J. Badimon \/ AstraZeneca"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aliskiren","moa":"Renin","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"HeartDrug Research","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aliskiren","moa":"Renin","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HeartDrug Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HeartDrug Research \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"HeartDrug Research \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Todd Doyle","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Todd Doyle","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Todd Doyle \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Todd Doyle \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire Saint Pierre","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire Saint Pierre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire Saint Pierre \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire Saint Pierre \/ AstraZeneca"},{"orgOrder":0,"company":"University of Palermo","sponsor":"AstraZeneca | University of Catania","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Palermo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Palermo \/ AstraZeneca | University of Catania","highestDevelopmentStatusID":"11","companyTruncated":"University of Palermo \/ AstraZeneca | University of Catania"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amsterdam UMC, VUmc \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC, VUmc \/ AstraZeneca"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ AstraZeneca"},{"orgOrder":0,"company":"Slotervaart Hospital","sponsor":"AstraZeneca | Isala | Spaarne Gasthuis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Slotervaart Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slotervaart Hospital \/ AstraZeneca | Isala | Spaarne Gasthuis","highestDevelopmentStatusID":"11","companyTruncated":"Slotervaart Hospital \/ AstraZeneca | Isala | Spaarne Gasthuis"},{"orgOrder":0,"company":"Maastricht University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Maastricht University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University \/ AstraZeneca"},{"orgOrder":0,"company":"LM Diagn\u00f3sticos S.L.","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LM Diagn\u00f3sticos S.L.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LM Diagn\u00f3sticos S.L. \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"LM Diagn\u00f3sticos S.L. \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Uppsala University \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register","highestDevelopmentStatusID":"11","companyTruncated":"Uppsala University \/ Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"AstraZeneca | Clinical Practice Research Datalink","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"University of Liverpool \/ AstraZeneca | Clinical Practice Research Datalink","highestDevelopmentStatusID":"11","companyTruncated":"University of Liverpool \/ AstraZeneca | Clinical Practice Research Datalink"},{"orgOrder":0,"company":"University of Dundee","sponsor":"NHS Tayside | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Dundee","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Dundee \/ NHS Tayside | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Dundee \/ NHS Tayside | AstraZeneca"},{"orgOrder":0,"company":"Gulf Regional Research & Educational Services, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gulf Regional Research & Educational Services, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gulf Regional Research & Educational Services, LLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gulf Regional Research & Educational Services, LLC \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ AstraZeneca"},{"orgOrder":0,"company":"Tulane University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tulane University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tulane University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"University of Michigan","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ AstraZeneca"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"University of Washington","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ AstraZeneca"},{"orgOrder":0,"company":"George Clinical","sponsor":"University Medical Center Groningen | Ground Zero Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"George Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Clinical \/ University Medical Center Groningen | Ground Zero Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"George Clinical \/ University Medical Center Groningen | Ground Zero Pharmaceuticals"},{"orgOrder":0,"company":"Centro de Diabetes Curitiba","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centro de Diabetes Curitiba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Diabetes Curitiba \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Centro de Diabetes Curitiba \/ AstraZeneca"},{"orgOrder":0,"company":"University of Campinas, Brazil","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Campinas, Brazil","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Campinas, Brazil \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Campinas, Brazil \/ AstraZeneca"},{"orgOrder":0,"company":"M.H.H. Kramer","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"M.H.H. Kramer","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M.H.H. Kramer \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"M.H.H. Kramer \/ AstraZeneca"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ganagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Provincial People\u2019s Hospital","sponsor":"Shandong Suncadia Medicine Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Henagliflozin Proline","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Zhejiang Provincial People\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Provincial People\u2019s Hospital \/ Shandong Suncadia Medicine Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang Provincial People\u2019s Hospital \/ Shandong Suncadia Medicine Co., Ltd."},{"orgOrder":0,"company":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Henggliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SLC5A2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Korea University Anam Hospital \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SLC5A2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Weill Medical College of Cornell University \/ Pacira BioSciences"},{"orgOrder":0,"company":"Nabiqasim","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Nabiqasim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabiqasim \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nabiqasim \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital T\u00fcbingen \/ German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"phlorozin derivatives||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"phlorozin derivatives||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"phlorozin derivatives||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"George Washington University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"George Washington University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"George Washington University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Foundation for Atlanta Veterans Education and Research, Inc.","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Foundation for Atlanta Veterans Education and Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation for Atlanta Veterans Education and Research, Inc. \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Foundation for Atlanta Veterans Education and Research, Inc. \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"The George Institute for Global Health, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ The George Institute for Global Health, Australia","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ The George Institute for Global Health, Australia"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"The George Institute for Global Health, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ The George Institute for Global Health, Australia","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ The George Institute for Global Health, Australia"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleveland Clinic \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"SINA Health Education and Welfare Trust","sponsor":"Horizon Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SINA Health Education and Welfare Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SINA Health Education and Welfare Trust \/ Horizon Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"SINA Health Education and Welfare Trust \/ Horizon Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Bundang Hospital \/ Celltrion","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Celltrion"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Hannover Medical School","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hannover Medical School","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hannover Medical School \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Hannover Medical School \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"The Deutsche Diabetes Forschungsgesellschaft e.V.","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"The Deutsche Diabetes Forschungsgesellschaft e.V.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Deutsche Diabetes Forschungsgesellschaft e.V. \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"The Deutsche Diabetes Forschungsgesellschaft e.V. \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Undisclosed"},{"orgOrder":0,"company":"German Diabetes Center","sponsor":"Boehringer Ingelheim GmbH | German Center for Diabetes Research | Federal Ministry of Health, Germany | Ministry of Innovation, Science and Research, NRW | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"German Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"German Diabetes Center \/ Boehringer Ingelheim GmbH | German Center for Diabetes Research | Federal Ministry of Health, Germany | Ministry of Innovation, Science and Research, NRW | Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"German Diabetes Center \/ Boehringer Ingelheim GmbH | German Center for Diabetes Research | Federal Ministry of Health, Germany | Ministry of Innovation, Science and Research, NRW | Novo Nordisk"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johannes Gutenberg University Mainz \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Johannes Gutenberg University Mainz \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Samaritan Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon State University \/ Samaritan Health Services","highestDevelopmentStatusID":"11","companyTruncated":"Oregon State University \/ Samaritan Health Services"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2||Sodium\/glucose cotransporter 2 (SGLT2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Severance Hospital | Samsung Medical Center | Kyung Hee University Hospital at Gangdong | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Severance Hospital | Samsung Medical Center | Kyung Hee University Hospital at Gangdong | Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Asan Medical Center \/ Severance Hospital | Samsung Medical Center | Kyung Hee University Hospital at Gangdong | Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ipragliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Kowa Company \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kowa Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Kowa Company","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Kowa Company"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Endocrinology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mitiglinide Calcium","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Mitiglinide Calcium","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Mitiglinide Calcium","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Central Arkansas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Central Arkansas Veterans Healthcare System","highestDevelopmentStatusID":"11","companyTruncated":"VA Office of Research and Development \/ Central Arkansas Veterans Healthcare System"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IBSA Institut Biochimique \/ Cromsource","highestDevelopmentStatusID":"11","companyTruncated":"IBSA Institut Biochimique \/ Cromsource"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arizona \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of Arizona \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Liprotamase","moa":"Triglyceride | Polypeptides | Starch","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Liprotamase","moa":"Triglyceride | Polypeptides | Starch","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Liprotamase","moa":"Triglyceride | Polypeptides | Starch","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Liprotamase","moa":"Triglyceride | Polypeptides | Starch","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Columbia University \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Amgen Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Acetylsalicilic Acid","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bayer AG"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Coimbra | Steno Diabetes Center Copenhagen | University of Southern Denmark | Sydvestjysk Sygehus","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bandim Health Project \/ University of Coimbra | Steno Diabetes Center Copenhagen | University of Southern Denmark | Sydvestjysk Sygehus","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ University of Coimbra | Steno Diabetes Center Copenhagen | University of Southern Denmark | Sydvestjysk Sygehus"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"First Affiliated Hospital of Harbin Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Affiliated Hospital of Chengde Medical University | The First Affiliated Hospital of Zhengzhou University | Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peking Union Medical College Hospital \/ First Affiliated Hospital of Harbin Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Affiliated Hospital of Chengde Medical University | The First Affiliated Hospital of Zhengzhou University | Chinese Academy of Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ First Affiliated Hospital of Harbin Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Affiliated Hospital of Chengde Medical University | The First Affiliated Hospital of Zhengzhou University | Chinese Academy of Sciences"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Biphasic Insulin Aspart","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"CeraVe","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Miami \/ CeraVe","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ CeraVe"},{"orgOrder":0,"company":"Technical University of Munich","sponsor":"Helmholtz Zentrum M\u00fcnchen | University Hospital Carl Gustav Carus | Kinderkrankenhaus auf der Bult | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Newcastle NHS Trust | Cambridge University Hospitals NHS Foundation Trust | Birmingham ","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 Vaccine BNT162b2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Technical University of Munich","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technical University of Munich \/ Helmholtz Zentrum M\u00fcnchen | University Hospital Carl Gustav Carus | Kinderkrankenhaus auf der Bult | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Newcastle NHS Trust | Cambridge University Hospitals NHS Foundation Trust | Birmingham ","highestDevelopmentStatusID":"11","companyTruncated":"Technical University of Munich \/ Helmholtz Zentrum M\u00fcnchen | University Hospital Carl Gustav Carus | Kinderkrankenhaus auf der Bult | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Newcastle NHS Trust | Cambridge University Hospitals NHS Foundation Trust | Birmingham "},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DA-2811","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"DongWha Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dasidiem","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"DongWha Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DongWha Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"DongWha Pharm \/ Undisclosed"},{"orgOrder":0,"company":"University of Ioannina","sponsor":"Libytec Pharmaceutical S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GREECE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Epavasc","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Ioannina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ioannina \/ Libytec Pharmaceutical S.A.","highestDevelopmentStatusID":"11","companyTruncated":"University of Ioannina \/ Libytec Pharmaceutical S.A."},{"orgOrder":0,"company":"Chemical Resources","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Fenugreek Extract","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chemical Resources","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemical Resources \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chemical Resources \/ Undisclosed"},{"orgOrder":0,"company":"Chemical Resources","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Fenugreek Seeds Extract","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Chemical Resources","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemical Resources \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chemical Resources \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Glargine Insulin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Sanofi"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Royal Surrey County Hospital NHS Foundation Trust | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IMP","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Leicester \/ Royal Surrey County Hospital NHS Foundation Trust | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Leicester \/ Royal Surrey County Hospital NHS Foundation Trust | AstraZeneca"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Integra Flowable Matrix Collagen","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Georgetown University \/ Integra LifeSciences","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Integra LifeSciences"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Jinlida","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Shijiazhuang Yiling Pharmaceutical Co.,Ltd."},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Pro-Omega LDL","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nordic Pharma \/ Nutrasource","highestDevelopmentStatusID":"11","companyTruncated":"Nordic Pharma \/ Nutrasource"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Hyaluronidase PH20","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-84)","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tan Tock Seng Hospital","sponsor":"Duke-NUS Graduate Medical School | National Healthcare Group, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SINGAPORE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tan Tock Seng Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tan Tock Seng Hospital \/ Duke-NUS Graduate Medical School | National Healthcare Group, Singapore","highestDevelopmentStatusID":"11","companyTruncated":"Tan Tock Seng Hospital \/ Duke-NUS Graduate Medical School | National Healthcare Group, Singapore"},{"orgOrder":0,"company":"Analgesic Solutions","sponsor":"Astellas Pharma | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Analgesic Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Analgesic Solutions \/ Astellas Pharma | Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Analgesic Solutions \/ Astellas Pharma | Pfizer Inc"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Iopamidol","moa":"X-ray contrast agent","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Sciema UG","sponsor":"Innovative Diabetes Treatment Studies","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sciema UG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sciema UG \/ Innovative Diabetes Treatment Studies","highestDevelopmentStatusID":"11","companyTruncated":"Sciema UG \/ Innovative Diabetes Treatment Studies"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Recordati Rare Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Recordati Rare Diseases"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          November 04, 2024

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Teplizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 07, 2023

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          September 23, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          05

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          November 10, 2021

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          06

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          August 12, 2021

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          07

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 28, 2021

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          08

                          Details : Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Exocrine Pancreatic Insufficiency.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 19, 2020

                          Lead Product(s) : Pancrelipase

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          09

                          Details : Testosterone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypogonadism.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 18, 2020

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          10

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          August 30, 2019

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner